Moreover, in hepatocellular carcinoma, it is indicated that RACGAP1 can activate RhoA to function, and it was verified that RACGAP1 enhances the stability of ECT2 to improve ECT2-mediated RhoA activation [3] (Figure 2d). The gene discussed is ECT2; the disease is hepatocellular carcinoma.